Hyperprogression to camrelizumab in a patient with esophageal squamous cell carcinoma harboring EGFR kinase domain duplication
Background Previous studies have reported that the amplification of some genes, such as Murine Double Minute 2 or 4 and Epidermal Growth Factor Receptor (EGFR), may be related to hyperprogressive disease (HPD). Exploring somatic gene alterations might be an effective method to predict HPD. Herein we...
Saved in:
| Main Authors: | Mei Wang, Meihong Wu, Minglu Liu, Zhengqing Yan, Guoqiang Wang, Dongliang Mao |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMJ Publishing Group
2020-05-01
|
| Series: | Journal for ImmunoTherapy of Cancer |
| Online Access: | https://jitc.bmj.com/content/8/1/e000793.full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Prospective multicenter study of camrelizumab in real-world settings for asian patients with esophageal squamous cell carcinoma
by: Tingting Li, et al.
Published: (2024-11-01) -
Efficacy and safety of camrelizumab combined with chemotherapy as second-line treatment for locally advanced, recurrent, or metastatic esophageal squamous cell carcinoma
by: Yinfang Gu, et al.
Published: (2025-02-01) -
Prognostic Value of GPNMB, EGFR, p-PI3K, and Ki-67 in Patients with Esophageal Squamous Cell Carcinoma
by: Bo Wang, et al.
Published: (2022-01-01) -
Anti-EGFR aptamer exhibits direct anti-cancer effects in NSCLC cells harboring EGFR L858R mutations
by: Brian J. Thomas, et al.
Published: (2024-11-01) -
Treatment Options for Non-Small Cell Lung Cancer Harboring Uncommon *EGFR* Mutations
by: Alfredo Addeo
Published: (2022-06-01)